All In Biotech

Drug Trial Radar · NCT07130175

Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)

Efficacy of Radiofrequency Catheter Ablation on Improving Cardiac Function in Patients With Polymorphic Ventricular Tachycardia and Coexisting Heart Failure: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Dec 31, 2022

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Qian FengAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The First Hospital of Zhangjiakou City
First posted
Aug 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, controlled trial to investigate the efficacy of radiofrequency catheter ablation (RFCA) combined with guideline-directed medical therapy (GDMT) compared to GDMT alone in patients with polymorphic ventricular tachycardia (PMVT) and coexisting heart failure (HF). The study aims to evaluate whether the addition of RFCA can lead to superior improvements in cardiac function, clinical outcomes, and serum biomarkers at a 6-month follow-up.

Conditions

  • Polymorphic Ventricular Tachycardia
  • Heart Failure

Interventions

  • Radiofrequency Catheter AblationDevice

    An invasive procedure performed under local anesthesia. An electroanatomic mapping system (CARTO 3) was used to identify the arrhythmogenic substrate of the PMVT. Radiofrequency energy was delivered via an irrigated-tip catheter (30-35 W, 43°C, 17 mL/min saline irrigation) to ablate the target sites. The procedural endpoint was the non-inducibility of the clinical arrhythmia. Post-procedure, patients were prescribed amiodarone.

  • Guideline-Directed Medical Therapy (GDMT)Drug

    Standard medical therapy for heart failure, including spironolactone (20 mg once daily), metoprolol succinate (25 mg twice daily), and sacubitril/valsartan (50 mg twice daily). Doses were titrated according to patient tolerance and clinical guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Left Ventricular Ejection Fraction (LVEF)Time frame: Baseline, 6 Months Post-treatment
  2. Change in Left Ventricular End-Diastolic Volume (LVEDV)Time frame: Baseline, 6 Months Post-treatment
  3. Change in Left Ventricular End-Systolic Volume (LVESV)Time frame: Baseline, 6 Months Post-treatment
  4. Change in Stroke Volume (SV)Time frame: Baseline, 6 Months Post-treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Zhangjiakou City

    Zhangjiakou, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.